Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
26 March 2009 - 10:00PM
PR Newswire (US)
BETHESDA, Md., March 26 /PRNewswire-FirstCall/ -- Micromet, Inc.
(NASDAQ: MITI), a biopharmaceutical company developing novel,
proprietary antibodies for the treatment of cancer, inflammation
and autoimmune diseases, today announced that its President and
CEO, Dr. Christian Itin, will present at the Future Leaders in the
Biotech Industry conference at the Millennium Broadway Hotel &
Conference Center in New York City on Thursday, April 2, 2009. A
simultaneous webcast of the presentation will be available on the
company's website at http://www.micromet-inc.com/ Forum: Future
Leaders in the Biotech Industry Date: Thursday, April 2, 2009 Time:
1:30 to 1:55 pm U.S. Eastern Time Place: The Millennium Broadway
Hotel & Conference Center New York City, New York Webcast:
http://www.micromet-inc.com/ About Micromet Micromet, Inc.
(http://www.micromet-inc.com/) is a biopharmaceutical company with
offices in Bethesda, MD and Munich, Germany. The Company is focused
on developing novel, proprietary antibodies for the treatment of
cancer, inflammation and autoimmune diseases. The Company's novel
antibody technology is based on its proprietary BiTE(R) antibody
platform, representing a new class of antibodies that specifically
activate T cells from the patient's own immune system to eliminate
cancer cells or other disease related cells. Four of the Company's
antibodies are currently in clinical trials, with the remainder of
its product pipeline in preclinical development. The Company's lead
program is a BiTE antibody known as blinatumomab, or MT103. It is
in a phase 2 clinical trial for the treatment of patients with
acute lymphoblastic leukemia and a phase 1 clinical trial for the
treatment of patients with non-Hodgkin's lymphoma. Micromet's
second BiTE antibody in clinical development is MT110, which
targets the epithelial cell adhesion molecule (EpCAM). The Company
owns all rights to MT110, which is currently in a phase 1 clinical
trial for the treatment of patients with solid tumors. The
Company's third clinical stage antibody is adecatumumab, also known
as MT201, a traditional human monoclonal antibody that targets
EpCAM-expressing solid tumors. Micromet is developing adecatumumab
in collaboration with Merck Serono in a phase 1b clinical trial
evaluating adecatumumab in combination with docetaxel for the
treatment of patients with metastatic breast cancer. Micromet
licensed a fourth clinical stage antibody, MT293, to TRACON
Pharmaceuticals, Inc. MT293 is being developed in a phase 1
clinical trial for the treatment of patients with cancer. The
Company's preclinical programs include MT203 being developed in
collaboration with Nycomed. MT203 is a traditional human antibody
neutralizing the activity of granulocyte/macrophage colony
stimulating factor (GM-CSF), which has potential applications in
the treatment of inflammatory and autoimmune diseases, such as
rheumatoid arthritis, psoriasis, or multiple sclerosis. Micromet
has granted an exclusive option to Bayer Schering Pharma AG to
license a BiTE antibody against an undisclosed solid tumor target.
Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and
MCSP, respectively, are in different stages of preclinical
development. Forward-Looking Statements This release contains
certain forward-looking statements that involve risks and
uncertainties that could cause actual results to be materially
different from historical results or from any future results
expressed or implied by such forward-looking statements. You are
urged to consider statements that include the words "ongoing,"
"may," "will," "believes," "potential," "expects," "plans,"
"anticipates," "intends," or the negative of those words or other
similar words to be uncertain and forward-looking. Factors that may
cause actual results to differ materially from any future results
expressed or implied by any forward-looking statements include the
risk that product candidates that appeared promising in early
research, preclinical studies or clinical trials do not demonstrate
safety and/or efficacy in subsequent clinical trials, the risk that
encouraging results from early research, preclinical studies or
clinical trials may not be confirmed upon further analysis of the
detailed results of such research, preclinical study or clinical
trial, the risk that additional information relating to the safety,
efficacy or tolerability of our product candidates may be
discovered upon further analysis of preclinical or clinical trial
data, the risk that we or our collaborators will not obtain
approval to market our product candidates, the risks associated
with reliance on outside financing to meet capital requirements,
and the risks associated with reliance on collaborators, including
MedImmune, Merck Serono, TRACON and Nycomed, for the funding or
conduct of further development and commercialization activities
relating to our product candidates. These factors and others are
more fully discussed in Micromet's Annual Report on Form 10-K for
the fiscal year ended December 31, 2008, filed with the SEC on
March 16, 2009, as well as other filings by the company with the
SEC. Any forward-looking statements are made pursuant to Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, and, as such,
speak only as of the date made. Micromet, Inc. undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise.
DATASOURCE: Micromet, Inc. CONTACT: US Media: Andrea tenBroek or
Chris Stamm, +1-781-684-0770, ; US Investors: Susan Noonan,
+1-212-966-3650, ; European Media: Ludger Wess, +49 (40) 8816 5964,
; European Investors: Ines-Regina Buth, +49 (30) 2363 2768, Web
Site: http://www.micromet-inc.com/
Copyright